OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2026
(1)
2021
(1)
2020
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.
Not available
S-EPMC13641261
|
biostudies-literature
Cite
Divergent mutational processes distinguish hypoxic and normoxic tumours.
Not available
S-EPMC7002770
|
biostudies-literature
Cite
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.
Not available
S-EPMC8245161
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
